Glover Stephen C. 4

What Happened
Stephen C. Glover, a director of Oncolytics Biotech Inc. (ONCY), was granted a derivative award on June 1, 2026 covering 96,000 shares (reported as acquired with a $0.00 acquisition amount). The filing indicates these are option-type awards: the exercise price is set equal to the closing price of ONCY common stock on the Nasdaq on the grant date (footnote). The award vests in three equal annual tranches, with the first tranche vesting on June 1, 2027, subject to continued service.

Key Details

• Transaction date: 2026-06-01 (Form 4 filed 2026-06-03). Filing appears timely (within the normal two-business-day window).
• Instrument and amount: 96,000 derivative shares (stock option award), reported acquisition amount $0.00 in the table.
• Exercise/strike price: Equals the closing price of ONCY common stock on Nasdaq on 2026-06-01 (per footnote). Specific dollar strike not listed in the summary table.
• Vesting: Three equal annual installments; first vesting on 2027-06-01, subject to continued service (per footnote).
• Shares owned after transaction: Not specified in the provided filing summary.
• Filing code: A (grant/award). No indication of 10b5-1 plan, tax withholding, or late filing in this report.

Context
This was a stock option/award grant (a non-sale, non-cash transaction). Such grants are typically retention/incentive awards and do not represent an immediate cash outlay or sale of shares; economic benefit depends on future vesting and, if exercised, the stock price relative to the strike. Because the strike was set at the market close on the grant date (at-the-money), value accrues only if the share price rises above that level after vesting.